Neurofibromatosis Type 2 Differential Diagnoses

1. Evans DG. Neurofibromatosis 2. Genet Med. 2009. 11:599-610. [QxMD MEDLINE Link].

2. Harris GJ, Plotkin SR, Maccollin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery. 2008 Jun. 62(6):1314-9; discussion 1319-20. [QxMD MEDLINE Link].

3. Aboukais R, Baroncini M, Zairi F, Bonne NX, Schapira S, Vincent C, et al. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien). 2013 May. 155(5):771-7. [QxMD MEDLINE Link].

4. Van Gompel JJ, Agazzi S, Carlson ML, Adewumi DA, Hadjipanayis CG, Uhm JH, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas. Neurosurgery. 2018 Feb 1. 82 (2):E52-E54. [QxMD MEDLINE Link].

5. Selch MT, Pedroso A, Lee SP, et al. Stereotactic radiotherapy for the treatment of acoustic neuromas. J Neurosurg. 2004 Nov. 101 Suppl 3:362-72. [QxMD MEDLINE Link].

6. Safavi-Abbasi S, Bambakidis NC, Zabramski JM, et al. Nonvestibular schwannomas: an evaluation of functional outcome after radiosurgical and microsurgical management. Acta Neurochir (Wien). 2010 Jan. 152(1):35-46. [QxMD MEDLINE Link].

7. Schwartz MS, Otto SR, Shannon RV, et al. Auditory brainstem implants. Neurotherapeutics. 2008 Jan. 5(1):128-36. [QxMD MEDLINE Link].

8. Matsuo M, Ohno K, Ohtsuka F. Characterization of early onset neurofibromatosis type 2. Brain Dev. 2013 Feb 13. [QxMD MEDLINE Link].

9. Beltrami S, Branchetti E, Sariyer IK, Otte J, Weaver M, Gordon J. Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma. PLoS One. 2013. 8(1):e53447. [QxMD MEDLINE Link]. [Full Text].

10. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain. 2008 Mar. 131:606-15. [QxMD MEDLINE Link].

11. Goutagny S, Bah AB, Parfait B, Sterkers O, Kalamarides M. Neurofibromatosis type 2 in the elderly population: Clinical and molecular features. Am J Med Genet A. 2013 Apr. 161(4):667-70. [QxMD MEDLINE Link].

12. Ruggieri M, Gabriele AL, Polizzi A, et al. Natural history of neurofibromatosis type 2 with onset before the age of 1 year. Neurogenetics. 2013. 14:89-98. [QxMD MEDLINE Link].

13. Goutagny S, Bah AB, Parfait B, et al. Neurofibromatosis type 2 in the elderly population: Clinical and molecular features. Am J Med Genet Part A. 2013. 161A:667-70. [QxMD MEDLINE Link].

14. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992. 304:603-18. [QxMD MEDLINE Link].

15. Hexter A, Jones A, Joe, H, et al. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet. 2015. 52:699-705. [QxMD MEDLINE Link].

16. Aboukais R, Zairi F, Baroncini M, Bonne NX, Schapira S, Vincent C, et al. Intracranial meningiomas and neurofibromatosis type 2. Acta Neurochir (Wien). 2013 Apr 5. [QxMD MEDLINE Link].

17. Fisher LM, Doherty JK, Lev MH, et al. Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2. Otol Neurotol. 2007 Dec. 28(8):1083-90. [QxMD MEDLINE Link].

18. Godel T, Bäumer P, Farschtschi S, Gugel I, Kronlage M, Hofstadler B, et al. Peripheral nervous system alterations in infant and adult neurofibromatosis type 2. Neurology. 2019 Aug 6. 93 (6):e590-e598. [QxMD MEDLINE Link].

19. Gugel I, Grimm F, Teuber C, Zipfel J, Tatagiba M, Mautner VF, et al. Presenting symptoms in children with neurofibromatosis type 2. Childs Nerv Syst. 2020 Oct. 36 (10):2463-2470. [QxMD MEDLINE Link].

20. Gaudioso C, Listernick R, Fisher MJ, Campen CJ, Paz A, Gutmann DH. Neurofibromatosis 2 in children presenting during the first decade of life. Neurology. 2019 Sep 3. 93 (10):e964-e967. [QxMD MEDLINE Link].

21. Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017 Jan 3. 88 (1):87-92. [QxMD MEDLINE Link].

22. Evans DG, Freeman S, Gokhale C, et al. Bilateral vestibular schwannomas in older patients: NF2 or chance?. J Med Genet. 2015 Jun. 52 (6):422-4. [QxMD MEDLINE Link].

23. Lee HBH, Garrity JA, Cameron JD, Strianese D, Bonavolonta G, Patrinely JR. Primary optic nerve sheath meningioma in children. Surv Ophthalmol. 2008. 53:543-58.

24. Bettegowda C, Upadhayaya M, Evans DG, Kim A, Mathios D, Hanemann CO, et al. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Neurology. 2021 Aug 17. 97 (7 Suppl 1):S91-S98. [QxMD MEDLINE Link].

25. Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, et al. Genetic Severity Score predicts clinical phenotype in NF2. J Med Genet. 2017 Oct. 54 (10):657-664. [QxMD MEDLINE Link].

26. Moualed D, Wong J, Thomas O, Heal C, Saqib R, Choi C, et al. Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants. Eur J Hum Genet. 2022 Jan 24. [QxMD MEDLINE Link].

27. Sestini R, Provenzano A, Bacci C, et al. NF2 mutation screening by denaturing high-performance liquid chromatography and high-resolution melting analysis. Genet Test. 2008 Jun. 12(2):311-8. [QxMD MEDLINE Link].

28. Ahlawat S, Fayad LM, Khan MS, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016 Aug 16. 87 (7 Suppl 1):S31-9. [QxMD MEDLINE Link].

29. Thompson HL, Blanton A, Franklin B, Merker VL, Franck KH, Welling DB, et al. Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials. Neurology. 2021 Aug 17. 97 (7 Suppl 1):S64-S72. [QxMD MEDLINE Link].

30. Otto SR, Brackmann DE, Hitselberger W. Auditory brainstem implantation in 12- to 18-year-olds. Arch Otolaryngol Head Neck Surg. 2004 May. 130(5):656-9. [QxMD MEDLINE Link].

31. Kanowitz SJ, Shapiro WH, Golfinos JG, et al. Auditory brainstem implantation in patients with neurofibromatosis type 2. Laryngoscope. 2004 Dec. 114(12):2135-46. [QxMD MEDLINE Link].

32. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23. 361(4):358-67. [QxMD MEDLINE Link].

33. Gugel I, Zipfel J, Hartjen P, Kluwe L, Tatagiba M, Mautner VF, et al. Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality. Childs Nerv Syst. 2020 Oct. 36 (10):2471-2480. [QxMD MEDLINE Link].

34. Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2012 Sep. 14 (9):1163-70. [QxMD MEDLINE Link].

35. Osorio DS, Hu J, Mitchell C, Allen JC, Stanek J, Hagiwara M, et al. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol. 2018 Sep. 139 (3):749-755. [QxMD MEDLINE Link].

36. von Eckardstein KL, Beatty CW, Driscoll CL, Link MJ. Spontaneous regression of vestibular schwannomas after resection of contralateral tumor in neurofibromatosis Type 2. J Neurosurg. 2010 Jan. 112(1):158-62. [QxMD MEDLINE Link]. [Full Text].

37. Gerszten PC, Burton SA, Ozhasoglu C, McCue KJ, Quinn AE. Radiosurgery for benign intradural spinal tumors. Neurosurgery. 2008 Apr. 62(4):887-95; discussion 895-6. [QxMD MEDLINE Link].

38. Colletti V, Shannon R, Carner M, Veronese S, Colletti L. Outcomes in nontumor adults fitted with the auditory brainstem implant: 10 years' experience. Otol Neurotol. 2009 Aug. 30(5):614-8. [QxMD MEDLINE Link].

David T Hsieh, MD, FAAP Associate Professor of Pediatrics and Neurology, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Chief, Physician Education, Joint Base San Antonio (JBSA)

David T Hsieh, MD, FAAP is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, Child Neurology Society

Disclosure: Nothing to disclose.

Luis O Rohena, MD, PhD, FAAP, FACMG Deputy Chief, Department of Pediatrics, Chief, Medical Genetics, San Antonio Military Medical Center; Associate Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD, PhD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

George I Jallo, MD Professor of Neurosurgery, Pediatrics, and Oncology, Director, Clinical Pediatric Neurosurgery, Department of Neurosurgery, Johns Hopkins University School of Medicine

George I Jallo, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association, American Society of Pediatric Neurosurgeons

Disclosure: Nothing to disclose.

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force, Department of Defense or the U.S. Government.

David A Griesemer, MD Professor, Departments of Neuroscience and Pediatrics, Medical University of South Carolina

David A Griesemer, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Neurology, American Epilepsy Society, Child Neurology Society, and Society for Neuroscience

Disclosure: Nothing to disclose.

Beth A Pletcher, MD Associate Professor, Co-Director of The Neurofibromatosis Center of New Jersey, Department of Pediatrics, University of Medicine and Dentistry of New Jersey

Beth A Pletcher, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, American Medical Association, and American Society of Human Genetics

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article